Logo

AstraZeneca Reports P-III Trial (AEGEAN) Results of Imfinzi (durvalumab) for Non-Small Cell Lung Cancer

Share this
AstraZeneca

AstraZeneca Reports P-III Trial (AEGEAN) Results of Imfinzi (durvalumab) for Non-Small Cell Lung Cancer

Shots:

  • The P-III trial (AEGEAN) evaluating Imfinzi (1500mg) + CT vs PBO + CT in 802 patients with resectable Stage IIA-IIIB NSCLC, irrespective of PD-L+1 expression at 264 centers in 25+ countries incl. in the US, Canada, EU, South America & Asia
  • The results showed that patients treated with Imfinzi + CT & as adjuvant monotx. achieved an improvement in EFS, results from the final pCR & mPR analyses were consistent with prior positive results, was well tolerated with no new safety concerns in the neoadjuvant & adjuvant settings
  • The combination therapy was consistent with the known profile. Imfinzi was approved in the US, EU, Japan, China & many other countries globally for extensive-stage SCLC, based on P-III trial (CASPIAN) results

Ref: AstraZeneca | Image: AstraZeneca

Related News:- AstraZeneca’s Imfinzi (durvalumab) + Imjudo (tremelimumab) Receives EU Approval for Advanced Liver and Non-Small Cell Lung Cancer

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions